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Neutrophil swarming and extracellular trap formation play a
significant role in Alum adjuvant activity
J. Stephen1, H. E. Scales1, R. A. Benson1, D. Erben1, P. Garside1 and J. M. Brewer1
There are over 6 billion vaccine doses administered each year, most containing aluminium-based adjuvants, yet we still do not have
a complete understanding of their mechanisms of action. Recent evidence has identified host DNA and downstream sensing as
playing a significant role in aluminium adjuvant (aluminium hydroxide) activity. However, the cellular source of this DNA, how it is
sensed by the immune system and the consequences of this for vaccination remains unclear. Here we show that the very early
injection site reaction is characterised by inflammatory chemokine production and neutrophil recruitment. Intravital imaging
demonstrates that the Alum injection site is a focus of neutrophil swarms and extracellular DNA strands. These strands were
confirmed as neutrophil extracellular traps due to their sensitivity to DNAse and absence in mice deficient in peptidylarginine
deiminase 4. Further studies in PAD4−/−mice confirmed a significant role for neutrophil extracellular trap formation in the adjuvant
activity of Alum. By revealing neutrophils recruited to the site of Alum injection as a source of the DNA that is detected by the
immune system this study provides the missing link between Alum injection and the activation of DNA sensors that enhance
adjuvant activity, elucidating a key mechanism of action for this important vaccine component.
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INTRODUCTION
Following its discovery in 1926,1 aluminium hydroxide (Alum) has
been unique in its prolonged use as an adjuvant in human
vaccines. Alum is known to induce a Th2 immune response,
characterised by the production of interleukin (IL)-4 and murine
IgG1 antibodies.
2 However, despite several theories being
proposed, the mechanism of action of Alum remains unclear.
Glenny originally suggested that Alum functioned through the
formation of a depot at the site of immunisation, resulting in the
slow release of antigen and/or sustained tissue inflammation.3
However, our recent work clearly demonstrates that removal of
the Alum injection site, as soon as 2 h after immunisation, had no
impact on the resulting adaptive immune response.4 While the
ability of Alum to trigger innate immune responses via the NLRP3
inflammasome and the subsequent production of proinflamma-
tory cytokines has been highlighted,5–7 the role of the inflamma-
some in mediating Alum function is controversial, with others
showing that key components of the inflammasome, such as
Nlrp3 and caspase 1, are dispensable for adjuvant activity.8,9 More
recently, interest has grown in the role of endogenous danger
signals, such as host DNA, in Alum adjuvant function. It has been
demonstrated that host DNA is accessible to enzyme (DNase)
degradation following Alum immunisation and plays a role in
driving antigen-specific T-cell response and B-cell response via
DNA sensors such as IRF3.10 Similarly, sensing of host DNA by
STING1 was shown to drive enhanced antigen presentation via
Dendritic Cells (DCs) and prolonged T cell–DC interactions
following Alum immunisation.11 Overall, these studies suggest
that release of host DNA plays a pivotal role in the adjuvant
function of Alum. However, the cellular source of this host DNA
and the mechanism of DNA release remain unclear. Here we
analyse the very early responses to Alum at the injection site and
demonstrate that neutrophils are the principal cell recruited
within 2 h of injection. Intravital imaging revealed neutrophil
swarming and cell death focussed around Alum, and the presence
of DNA strands within the tissue. These strands were subsequently
confirmed as neutrophil extracellular traps (NETs) via their
sensitivity to DNase treatment. NETs were also absent in PAD4-
deficient mice, which also displayed markedly reduced immune
responses following Alum injection. These studies demonstrate
that the mechanism of neutrophil death plays an important role in
the adjuvant activity of Alum, and explain how the cellular
reaction at the injection site drives the liberation of host DNA,
which subsequently impacts on adjuvant activity.
RESULTS
Alum rapidly establishes an inflammatory milieu following
injection
Previous studies using ear pinna injection site ablation demon-
strated that the injection site and any inflammatory reaction
occurring therein was dispensable for adjuvant activity within 2 h
post injection.4 Clearly, for any inflammatory response to play a
role in adjuvant activity, it would have to occur within that narrow
time frame. Analysis of Ly6G+CD11b+ neutrophils at the site of
immunisation 2 h after ovalbumin (OVA)/Alum injection demon-
strated an increased frequency (Fig. 1a) and number (Fig. 1b) of
these cells at the site of immunisation compared with controls (UT;
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Fig. 1 Alum induces neutrophil recruitment at the site of immunisation but not at the dLN within 2 h. a Representative flow cytometry plots
depicting the recruitment of Ly6G+CD11b+ neutrophils to the site of alum immunisation. bMean number (±SEM) of Ly6G+ neutrophils, F4/80+
macrophages and CD11c+ dendritic cells recruited within 2 h to the alum injection site (UT; Untreated, PBS; PBS-injected). Groups contained
six animals and data are representative of three independent experiments. c Representative flow cytometry plots and bar charts depicting the
mean number of Ly6G+CD11b+ neutrophils (±SEM) recruited to the draining cervical LN 2 h and d 24 h post immunisation. Groups contained
three to five animals and data are representative of three independent experiments. **P< 0.01, ***P< 0.001
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untreated control, PBS (phosphate-buffered saline); ears injected
with PBS). The inflammatory site induced by Alum at this time was
characterised by the presence of neutrophils, as there were no
significant differences in the number of F4/80+ macrophages or
CD11c+ DCs (Fig. 1b). In contrast with the site of immunisation,
Alum did not induce neutrophil recruitment to the draining lymph
node (dLN) compared with OVA-immunised controls 2 or 24 h
following immunisation, whereas significant neutrophil recruit-
ment could be found 2 h following lipopolysaccharide (LPS)
injection (Fig. 1c, d). Analysis of inflammatory cytokine and
chemokine transcription revealed significant increases in IL-1β,
CCL2, CXCL1 and CXCL2 transcripts at the OVA/Alum injection site
within 2 h (Fig. 2a). Furthermore, inflammatory responses were
also evident within the dLN at this time point (Fig. 2b), indicating
the rapid dissemination of the inflammatory response from the
tissue to the draining LN. Together, these data demonstrate that
Alum induces an intense and rapid inflammatory response at the
injection site that quickly impacts on the dLN.
Injection of Alum induces neutrophil recruitment and swarming at
the site of immunisation
To investigate the cellular dynamics and behaviour of recruited
neutrophils, we took advantage of the ability to visualise the Alum
injection site in the ear pinna of LysM-eGFP reporter mice using
multiphoton microscopy without the requirement for surgery.12
OVA alone or OVA/Alum was injected into the ear pinna of LysM-
eGFP mice. While a small number of GFP+ neutrophils were
observed at the OVA injection site (Fig. 3a; Supplementary Movie
1) treatment with OVA/Alum produced greatly enhanced neu-
trophil recruitment (Fig. 3b; Supplementary Movie 2) consistent
with the flow cytometric analysis (Fig. 1a, b). The movement of
cells in the OVA/Alum-treated mice also appeared different to that
observed in control OVA-treated mice. The area around OVA/Alum
injection sites contained neutrophils displaying highly directional,
linear motility (Fig. 3c; Supplementary Movie 3) with a bimodal
distribution of turning angle of 0° (directly towards) or 180°
(directly away from) the Alum injection site (Fig. 3d). This
migration resulted the formation of clusters of neutrophils (Fig. 3e;
Supplementary Movie 4). The presence of Alum at the core of
these clusters was confirmed using fluorescently labelled protein
adsorbed to Alum (Fig. 3f; Supplementary Movie 5). The neutrophil
identity of the GFP+ cells was confirmed by flow cytometry (FACS)
analysis that demonstrated fourfold higher expression of GFP in
neutrophils compared with monocytes and macrophages. This
was reflected in the GFP dim, resident cells in untreated ears,
presumably macrophages (Fig. 1b) that did not resemble the GFP
bright, swarming neutrophils seen after Alum injection (Supple-
mentary Figure 1). Overall, the imaging data demonstrate that
Alum rapidly induces the recruitment of GFP+ neutrophils to the
site of injection and that these neutrophils swarm around deposits
of Alum found at the injection site.
Alum induces neutrophil cell death and the release of extracellular
DNA at the site of immunisation within two hours in vivo
Using the cell-impermeant DNA dye, Sytox Orange, we examined
cell death and DNA release at the injection site in LysM-eGFP mice.
Nuclear staining could be observed in GFP-positive neutrophils as
well as GFP-negative cells, which, given the inflammatory profile
established in Fig. 1, were presumably tissue-resident cells (Fig. 4a,
b). Closer analysis of injection sites in Alum-treated mice (Fig. 4a)
also revealed Sytox Orange-positive strands (arrowheads) that
were not visible in OVA-treated animals (Fig. 4b). Higher-
resolution, three-dimensional (3D)-rendered images of these
extracellular DNA protrusions identified using Hoescht 33342
displayed the characteristic features of NETs (Fig. 4c). Treatment of
OVA/Alum-immunised mice with DNAse resulted in loss of these
structures, confirming the identity of these strands as extracellular
DNA (Fig. 4d). Previous studies have demonstrated that deimina-
tion of histones H3 and H4 by peptidylarginine deiminase 4
(PAD4) is required for NET formation, and consequently
Fig. 2 Inflammatory chemokine and cytokine expression at the site of immunisation and dLN 2 h after Alum injection. Representative
examples of inflammatory chemokine and cytokine expression at a the site of alum injection (three animals per group) and b draining cervical
lymph nodes (three to seven animals per group). Data are representative of two independent experiments. *P<0.05,
**P< 0.01
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neutrophils from PAD4ko mice fail to undergo netosis.13,14
PAD4ko mice therefore provided a means to confirm the identity
of the Alum-induced strands as NETs, as well as an approach to
reveal the functional role of netosis in Alum adjuvant activity.
Intravital multiphoton laser scanning microscopy (MPLSM) analysis
2 h after OVA/Alum injection of PAD4ko mice failed to identify
DNA strands (Fig. 4e) at the injection site, while these structures
were abundant in PAD4 replete littermate mice (Fig. 4f), confirm-
ing their identity as NETs. Finally, immunohistochemistry of whole-
mount ears following Alum injection revealed Histone H3 and
Fig. 3 Alum induces neutrophil recruitment and swarming at the site of immunisation within 2 h. LysM-eGFP mice were injected with a OVA
alone or b OVA/Alum 10min prior to intravital MPLSM. While some neutrophil recruitment could be observed following injection of OVA,
substantially more neutrophils were observed following OVA/Alum injection. c Tracking GFP+ neutrophils using a dragon plots demonstrated
highly linear, directional movement in tissue and d this was quantified using analysis of turning angle. e This directional movement resulted in
the formation of localised neutrophil ‘swarms’. f Immunisation with Alexa-647-labelled alum confirmed that the neutrophils were swarming
around deposits of alum at the site of injection. Images shown are representative of three independent experiments
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DNA (Sytox Orange) co-localising within NETs, with a local release
of myeloperoxidase evident at the injection site (Fig. 4g).
Deletion of the PAD4 enzyme affects the polarisation of the
adaptive immune response to alum adjuvant
Next we sought to determine whether the formation of NETs at
the Alum injection site plays a role in driving the adjuvant
activity of Alum by analysing antigen-specific T (OTII) and B cell
(MD4) responses following adoptive transfer to PAD4ko and
wild-type (WT) mice. At the peak of the antigen-specific T-cell
response, 5 days after immunisation,15 PAD4ko mice had
significantly (P < 0.05) lower OVA-specific, OTII T cells as a
proportion of the T-cell population (Fig. 5b). Analysis of antigen-
specific MD4, B cells on day 7 after immunisation revealed that a
similar proportion of the B-cell population in PAD4ko mice were
IgMa+ HEL-specific (Fig. 5c), however, the ability of these cells to
form GL7+ FAS+ germinal centre B cells was significantly lowered
(P < 0.05) compared with WT control mice (Fig. 5d). Subsequently,
we determined levels of IgG1, characteristic of Alum adjuvant
activity and IgG2c, which is associated with a Th1 response.
Immunisation of PAD4ko mice with OVA/Alum resulted in
Fig. 4 Alum induces cell death and the release of NETs at the site of immunisation. Cell nuclei became accessible to the cell-impermeant DNA
dye, Sytox orange following a Alum/OVA or b OVA injection of LysM-eGFP mice. a Neutrophil (GFP+) nuclei only became Sytox orange-positive
following Alum/OVA injection, and this was accompanied by the appearance of long strands of stained DNA (arrowheads). c High-resolution-
rendered images using cell-permeant Hoechst 33342 nuclear dye at the injection site confirmed that these structures resembled NETs. d
DNAse treatment at the site of alum immunisation degraded the extracellular DNA structures released from neutrophils, visualised with
Hoechst 33342. Images in a, b are representative of n= 3, c, d of n= 5. (e) OVA/Alum does not induce the release of extracellular traps at the
site immunisation in PAD4KO mice compared with f control littermates. NETs were visualised using Hoechst 33342 as above, and data shown
are representative of five mice. g Histone H3 and DNA (Sytox Orange) co-localise within NETs, with a local release of myeloperoxidase evident
at the injection site
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significantly decreased IgG1 antibody production compared to WT
mice while IgG2c production was unchanged (Fig. 5e, f). OVA-
specific responses following immunisation with antigen prepared
in an alternative adjuvant, ISCOMATRIX (IMX), were similar in both
PAD4ko and control mice, indicating a specific loss of
responsiveness to Alum adjuvant (Fig. 5g, h). Collectively, these
studies demonstrate that PAD4-dependent netosis at the Alum
injection site plays a significant role in the ability of Alum to act as
an adjuvant that promotes B-cell differentiation and IgG1 antibody
production.
Fig. 5 Deletion of PAD4 affects the magnitude of the adaptive immune response induced by alum adjuvant. Antigen-specific T (OTII) and B
cells (MD4) were adoptively transfered to PAD4ko and WT mice. a Five days after immunisation, PAD4ko mice had similar numbers of cells in
dLNs; b however, the proportion of antigen-specific OTII T cells was significantly lower in PAD4ko compared with WT mice (*P< 0.05). c
Analysis of antigen-specific B cells on day 7 after immunisation revealed a similar proportion of the B-cell population in PAD4ko mice were
IgMa+ HEL-specific; d however, the fewer GL7+ FAS+ germinal centre B cells were observed (*P< 0.05) compared with WT control mice. e
PAD4KO mice immunised with OVA/Alum show reduced OVA-specific IgG1 titres compared with WT littermates 14 days after immunisation. f
Levels of antigen-specific IgG2c antibodies are undetectable in both strains of mouse. g, h Antigen-specific IgG1 and IgG2a responses were
similar in WT and PAD4KO mice 14 days after immunisation with OVA/ISCOMATRIX. Levels of antigen-specific IgG2c antibodies are
undetectable in both strains of mouse. Antibody analysis was performed on two to four mice per group, and data are representative of two to
three experiments. *P<0.05, **P< 0.01, ***P< 0.001
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DISCUSSION
Our studies demonstrate that Alum induces a rapid recruitment,
swarming and PAD4-dependent netosis following injection and
furthermore that this response is responsible for a significant
portion of the adjuvant effect induced by Alum.
These findings are consistent with our previous studies
demonstrating that key events in Alum adjuvant function
occurred within the first 2 h following immunisation.4 Recruitment
of neutrophils to the site of Alum injection was particularly rapid
compared with LPS, observable within minutes of injection and
reaching a peak within 2 h, consistent with previous reports in
models of sterile inflammation.16 Following injection of antigen
alone we observed a small increase in neutrophil recruitment in
tissue by both FACS and intravital MPLSM; however, the presence
of NETs was associated with a significant increase in neutrophil
recruitment, suggesting NETs may act to amplify neutrophil
recruitment by Alum, as previously observed in models of sterile
tissue injury.16
Although first described as having an important role in innate
immunity against bacteria,17 our data and those of previous
studies18,19 support a role for NETs in shaping the adaptive
immune response. NETs have been described in response to a
number of infectious20 and sterile challenges16,21,22 in vivo;
however, this is the first description of Alum inducing extracellular
trap formation by neutrophils. Previous studies reported that Alum
was able to induce fibrin extracellular traps at the site of
immunisation,23 which were composed of fibrin, extracellular
chromatin, citrullinated histones and were dependent on fibrino-
gen for formation. In contrast to our findings, Munks et al.
suggested that these extracellular structures were independent of
neutrophils and were not required for the adjuvant activity of
Alum.23 This discrepancy with our current findings likely arises
from the characterisation and location of these structures. Munks
et al. focussed on the fibrin component, showing that neutrophil-
depleted mice formed fibrin nodules without assessing the nucleic
acid composition. Furthermore the intraperitoneal route of
immunisation exposes a number of specialised resident cell
populations that are not found in subcutaneous tissue,24,25 in
particular the large peritoneal macrophages that disappear rapidly
after inflammatory challenge.24 In the skin, neutrophils are the
principal cell population recruited to the skin in response to Alum,
and we now show for the first time these cells swarm towards
Alum injection sites. PAD4 expression is broadly restricted to
neutrophils and peritoneal macrophages within the murine
immune system,13,14,26 and the absence of NETS observed in
PAD4-deficient mice indicates that neutrophils are the most likely
source of NETS forming in the skin in response to Alum.
A role for DNA released at the Alum injection site in adjuvant
function has previously been demonstrated as treatment with
DNAse following Alum immunisation reduced antigen-specific
CD4 T-cell activation and IgG and IgE antibody responses.10
However, the cellular source and sensing of this DNA remained
unclear. We now show that the very early inflammatory response
to Alum drives neutrophil recruitment and generates free DNA via
PAD4-dependent netosis. This response enhances antigen-specific
T expansion and B-cell differentiation leading to an increased,
class-switched antibody response. In the context of vaccination,
these studies demonstrate that the later inflammation evident at
the Alum injection site is superfluous for adjuvant activity and
furthermore suggest that components released during the
neutrophil netosis response may have utility as vaccine adjuvants.
METHODS
Mice
Six to eight-week-old female BALB/c mice were purchased from Harlan
(Bicester, UK). LysM-eGFP mice were a kind gift from Professor Sussan
Nourshargh. These mice have the gene for eGFP knocked into the
Lysozyme (Lys) M locus resulting in mice with fluorescent myelomonocytic
cells, with neutrophils comprising the highest percentage of eGFPhi cells.12
PAD4-floxed mice were a kind gift from Dr Kerri Mowen.13 To generate
PAD4-KO mice and control littermate mice, PAD4-floxed mice were crossed
with the ella cre deleter strain (B6.FVB-Tgn(Ella-Cre)C5379Lmgd (Charles
River, UK). Male and female PAD4-KO mice and control littermate mice
were used at 7–16 weeks of age. OT-II TCR Tg mice27 and MD4 BcR Tg
mice28 on C57BL/6 backgrounds were used as a source of OVA-specific
T cells and HEL-specific B cells, respectively. All mice were either injected
subcutaneously (s/c) in the ear pinna with 10 μl or in the scruff with 100 μl
of antigen/adjuvant suspensions. Mice were immunised with either 100 μg
of chromatographically purified chicken OVA (Worthington Biochemical,
Lakewood, NJ, USA), or OVA-HEL conjugate prepared using glutaraldehyde
to couple the chicken OVA and HEL (Sigma, Dorset, UK) as published.15
Antigens were prepared in a 1% Alum suspension (a gift from Dr Erik
Lindblad, Brenntag Biosector, Denmark) or in 1IU ISCOMATRIX (a kind gift
from CSL Limited, Australia) or 1 μg LPS (E. coli 0111:B4; Sigma Aldrich, UK).
To identify the site of injection, mice were also injected Alexa-647-labelled
OVA prepared using an Alexa-647 protein labelling kit (Thermo Fisher
Scientific) according to the manufacturer’s instructions. All buffers and
media were purchased endotoxin-free and absence of appreciable
endotoxin contamination of proteins was confirmed by absence of bone
marrow-derived dendritic cell activation at a dose of 500 µg. Animals were
allocated to experimental groups by a blinded observer, and were
maintained under standard animal house conditions at the University of
Glasgow and procedures were performed according to UK Home Office
regulations.
Taqman low-density arrays
Ear tissue and superficial cervical dLNs were excised and stored in RNAlater
(Qiagen). RNA was extracted using the RNeasy mini kit (Qiagen) according
to the manufacturer’s instructions and was homogenised using a
gentleMACs Dissociator (Miltenyi Biotech, UK). RNA was converted to
cDNA using a reverse transcription kit from Primer Design (Primer Design
Ltd, Southampton, UK). One μg of cDNA was then loaded onto customised
Taqman low-density array (TLDA) plates (Applied Biosystems, Life
Technologies, Paisley, UK) and probed for the presence of cytokine and
chemokine genes. Samples were subsequently analysed on an Applied
Biosystems 7900HT Fast Real-Time PCR System, using the SDS2.4 software.
Data were analysed on the RQ Manager 1.2.1 software. Data are shown as
fold change over the appropriate untreated control tissue. For analysis of
the injection site (ear) n = 3 for each treatment group; for analysis of the
dLNs n = 5 for the OVA-treated group, n = 7 for the OVA/ALUM-treated
group and n = 3 for the untreated, the PBS and the LPS-treated groups.
Where a target transcript was undetectable an arbitrary value of 0.001
was assigned. The data shown are representative of two independent
experiments.
Flow Cytometry
Cell suspensions were prepared from ear tissue by digestion in 2mg/ml
Collagenase IV and 2mg/ml Hyaluronidase (both from Sigma Aldrich) and
DNaseI (100 U/ml; Invitrogen) at 37 °C for 30min, followed by homo-
genisation using a gentleMACs Dissociator (Miltenyi Biotech). The draining
superficial cervical lymph node was gently teased apart using 26G needles
and digested in 2.68mg/ml collagenase D (Roche) for 25min at 37 °C. The
enzymatic reaction was stopped with a final concentration of 10mM EDTA.
A single cell suspension was then obtained by passing the lymph node
suspension through a 70 μm cell strainer. Single cell suspensions were then
stained with combinations of the following antibodies CD11c–PerCP-Cy5.5
(N418; Cat. No. 45-0114; eBioscience, Hartfield, UK), CD11b–PE-Cy7 (M1/70;
Cat. No. 25-0112; eBioscience), F4/80–APC (BM8; Cat. No. 123116;
BioLegend, San Diego, USA) CD45-eFluor®450 (30-F11; Cat. No. 48-0451;
eBioscience), Ly6-G–PE (IA8; Cat. No. 127608; BioLegend), MHCII–FITC (2G9;
Cat. No. 553623; BD Biosciences, UK), anti-B220-eFluor®450 (RA3-6B2;
Cat. No. 48-0452; eBioscience), anti-GL-7-FITC (GL7; Cat. No. 553666
BD Biosciences), anti-FAS-PE-Cy7 (Jo2; Cat. No. 557653; BD Biosciences),
anti-CD45.1-APC (A20; Cat. No. 558701; BD Biosciences), anti-CD4-PE-Cy5
(GK1.5; Cat. No. 100409, BioLegend), anti-Vb5.1/5.2-PE (MR9-4; Cat. No.
553190; BD Biosciences) and biotinylated anti-IgMa (DS-1; Cat. No.553515;
BD Biosciences). Streptavidin-APC-eFluor®780 (Cat. No. 47-4317; eBios-
ciences) was used to detect the biotinylated antibody. The viability of the
cells was confirmed using a fixable viability stain conjugated to eFluor®450
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(eBioscience). All antibodies and isotype controls were added to samples at
a dilution of 1:200. Samples were read using a MACSQuant flow cytometer
(Miltenyi Biotech, UK) and analysed using Flowjo software (Version 9.4 or
10.0.8; Treestar). For analysis of innate cell recruitment to the injection site
group sizes of six mice were used. The data shown are representative of
three independent experiments. For analysis of innate cell recruitment to
the dLN a group size of four was used for OVA treatment; five for OVA/
ALUM treatment and three for LPS treatment. Using data from previous
studies29 we estimated three mice would provide 80% power to detect
significant differences (a < 0.05) in numbers of neutrophils recruited to
tissue in response to adjuvant vs. PBS control. For the analysis of T-cell
transfer and B-cell transfer into PAD4KO and WT mice on day 5 the group
size was n = 3 and on day 7 the group size was n = 4 for WT mice and n = 3
for PAD4KO mice. The data shown are representative of two independent
experiments. Using previous data,30 we estimated three mice per time
point will provide 80% power to detect significant differences (a < 0.05) in
numbers of Plasma B cells induced by antigen and adjuvant vs. antigen
alone.
Enzyme linked immunosorbent assay
OVA-specific IgG1 and IgG2a/IgG2c titres were determined in serum samples
collected 14 days after immunisation as previously described.2 For the
analysis of antibody responses to OVA/ALUM the group sizes were n = 3
while for the analysis of antibody responses to OVA/IMX the group sizes
were n = 4 with n = 2 for PBS-treated controls. The data shown are
representative of three independent experiments.
In vivo multiphoton imaging
Multiphoton imaging was performed with a Zeiss LSM7 MP system
equipped with both a 10×/0.3 numerical aperture (NA) air and a 20×/1.0
NA water immersion objective lens (Zeiss) and a tunable titanium/sapphire
solid state two-photon excitation source (Chamelon Ultra II; Coherent Laser
Group). For in vivo imaging, animals were anaesthetised with fentanyl/
fluanisone (Hypnorm: Janssen Animal Health) and midazolam injectable
anaesthesia (Hypnovel: Roche; 10ml/kg of an aqueous mix of fentanyl/
fluanisone/ midazolam at 1:1:2 by volume) given intraperitoneally. Core
body temperature was continuously monitored and maintained by a
thermostatically controlled heat mat. The ear of interest was mounted on a
purpose-built, heated stand with the use of veterinary-grade glue
(Vetbond; 3M), enabling maintenance of tissue at 37 °C throughout the
experiment.31 Intravenous injection of non-targeted quantum dots
(Qtracker 655 and 705; Invitrogen) allowed highlighting of blood vessels.
Cells were visualised in the ear pinna using the cell-permeable DNA dye
Hoechst 33342 (Sigma Aldrich, UK) and extracellular DNA visualised with
SYTOX orange (Molecular Probes, Invitrogen, Paisley, UK). The dyes were
administered subcutaneously along with the antigen/adjuvant prepara-
tions. Mice were also treated subcutaneously in the ear pinna with 5mg of
DNase along with antigen/adjuvant preparations to block NET formation at
the injection site.17 Videos were acquired for 15–30min at an X–Y pixel
resolution 512 × 512 with 2.5-μm increments in Z. 3D tracking was
performed with both Imaris 7 (Bitplane) and Volocity 5.5 (Perkin Elmer)
after correction for tissue drift.
Whole-mount staining
Ears were carefully split into dorsal and ventral halves and fixed in 2%
paraformaldehyde prepared in PBS (PFA/PBS) (eBiosciences) for 30min on
ice. Fixed ears where then permeabilised in 0.2% Triton X-100 (Sigma)/PBS
on ice for 15min, and blocked overnight at 2–8 °C with 10 µg/ml anti-
CD16/CD32 (2.4G2; Cat. No. 553142; BD Biosciences), 5% Normal mouse
serum, 0.2% Triton X-100 in PBS. FITC conjugated anti-MPO (2D4; Cat. No.
ab90812; Abcam, UK) and purified rabbit anti-citrulinated Histone H3
(Polyclonal; Cat. No. ab5103; Abcam, UK) were added to give a final
concentration of each at 2 µg/ml and incubated at 2–8 °C overnight.
Tissues were washed in three changes of 0.2% triton X-100/PBS at 2–8 °C
for 1 h. The Alexafluor 647-conjugated secondary antibody (Goat anti-
Rabbit IgG; Cat. No. ab150083; Abcam) was added at 2 µg/ml in 2% NMS/
0.2% Triton X-100/PBS overnight at 2–8 °C. Tissues were washed in three
changes of 0.2% Triton X-100/PBS at 2–8 °C for 1 h. Sytox Orange was
added at a 1/10,000 dilution in 0.2% Triton X-100/PBS and incubated at
2–8 °C for 1 h. Tissues were then fixed in 1% PFA/PBS and imaged on the
multiphoton microscope.
Statistics
For flow cytometry and enzyme linked immunosorbent assay data,
intergroup significance was determined by either a one-way ANOVA or a
two-way ANOVA with a Tukey post test. For TLDA data intergroup
significance was determined using the non-parametric Kruskal–Wallis test
with a Dunns post test. Statistical analysis was performed using GraphPad
Prism 6 (GraphPad Software Inc., La Jolla, USA). A value of P≤ 0.05 was
considered significant.
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